Radiopharmaceutical developer Navidea Biopharmaceuticals has enrolled the first patient in a clinical study that will evaluate the use of its Lymphoseek radiopharmaceutical in women with known cervical cancer.
In support of Navidea's existing Lymphoseek label in lymphatic mapping, the study will assess Lymphoseek's performance in sentinel lymph node biopsy during cervical cancer surgery, according to the vendor. Principal investigator Dr. Michael Frumovitz of MD Anderson Cancer Center enrolled the first patient in the trial, which is intended to enroll up to 40 women at up to six U.S. sites.
The study is being funded by a fast-track grant from the U.S. National Cancer Institute.
